Watson Secures Affirmance of Reverse Payment Claims Dismissal

Skadden secured the affirmance of a dismissal for generic drug manufacturer Watson Pharmaceuticals, Inc. in a reverse payment suit brought by the Federal Trade Commission related to the testosterone replacement drug Androgel. On April 25, a panel for the U.S. Court of Appeals for the Eleventh Circuit agreed with the lower court's 2010 dismissal (also handled by Skadden) that the defendants, including the brand holder Solvay Pharmaceuticals, Inc. and Watson, did not violate federal and state antitrust laws when they settled patent infringement litigation with respect to generic versions of Androgel.